Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Down 30.6% in March

Jasper Therapeutics, Inc. (NASDAQ:JSPRGet Rating) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 130,700 shares, a decline of 30.6% from the March 15th total of 188,400 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 90,300 shares, the days-to-cover ratio is currently 1.4 days.

JSPR has been the topic of several analyst reports. Cantor Fitzgerald initiated coverage on shares of Jasper Therapeutics in a research report on Monday, February 28th. They set an “overweight” rating and a $10.00 price target on the stock. Zacks Investment Research raised shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 20th. Finally, Credit Suisse Group lowered their price objective on shares of Jasper Therapeutics from $15.00 to $10.00 and set an “outperform” rating on the stock in a research note on Friday, February 25th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.00.

Several institutional investors have recently added to or reduced their stakes in JSPR. Goldman Sachs Group Inc. acquired a new position in Jasper Therapeutics in the 4th quarter valued at about $139,000. Millennium Management LLC acquired a new position in Jasper Therapeutics in the 4th quarter valued at about $156,000. Tudor Investment Corp Et Al acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $205,000. Northern Trust Corp acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth approximately $159,000. Finally, Virtu Financial LLC acquired a new position in shares of Jasper Therapeutics during the 4th quarter worth approximately $163,000. Institutional investors own 82.99% of the company’s stock.

Shares of Jasper Therapeutics stock traded down $0.05 during trading on Friday, hitting $2.85. 55,938 shares of the stock were exchanged, compared to its average volume of 79,609. The stock has a fifty day moving average of $3.61. Jasper Therapeutics has a 1-year low of $2.85 and a 1-year high of $18.88.

About Jasper Therapeutics (Get Rating)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.

Further Reading

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.